Healthbeautyidea.com | Semaglutide For Weight Loss – For those of you who have a problem of obesity, or overweight, you can overcome it by taking diabetes medication. The recommendations are based on a new study by researchers across the UK.
According to the U.S. Centers for Disease Control and Prevention (CDC), 42 percent of Americans are obese, meaning they have a body mass index of 30 or more. Obesity increases the risk of heart disease, cancer, stroke and diabetes.
Semaglutide For Weight Loss
A diabetes drug that can be used to lose weight, namely Semaglutide. The researchers said the drug could help obese people lose weight, up to 15 percent, for 16 months.
British medical journal report
The report, published in the New England Journal of Medicine, says Semaglutide can reduce appetite. Drug manufacturers in the United States are asking the government to grant Semaglutide permission as a weight loss drug.
A recent study showed that diabetes drugs can play a role in losing weight of obese people.
A total of 1,961 older persons from North America, South America, Asia and Europe took part in the 68-week trial throughout 2018.
In it used semaglutide drugs or anti-diabetes drugs commonly used for the treatment of type 2 diabetes.
These people receive injections of semaglutide under the skin and some get a placebo every week.
In addition, respondents also participated in counseling sessions for low-calorie diets and increased exercise.
Semaglutide was sold under the names Ozempic and Rybelsus by Danish drug company Novo Nordisk.
Participants aged 18 and over, with one or more previous dietary effort to lose weight were more likely to have a normal body mass index (BMI) of between 18.5-24.9.
The researchers say that treatment with semaglutide once a week plus healthy lifestyle interventions can be weight loss for obese older persons (without diabetes) and sustaining.
Clinically the treatment was highly relevant to 14.9 percent, with 86 percent of participants achieving at least five percent weight loss.
Novo Nordisk sends semaglutide as a weight management treatment for regulatory approval to the Food and Drug Administration, the United States, and the European Medicines Agency.
The benefits of this weight loss are obtained from the decrease in body fat. This drug will decrease appetite, so people will tend to eat less.
The team of scientists said that Semaglutide targets specific receptors in the brain that can affect the hunger control system in the brain. The team of scientists stated that Semaglutide is more effective than other anti-obesity drugs, where the effects of weight loss can be felt for 12 weeks after taking Semaglutide compared to 6 months when using other drugs.
Developed by Novo Nordisk
Semaglutide is a new diabetes drug developed by Novo Nordisk. Its chemical structure is very similar to the natural hormone GLP-1 which is believed to have action on the appetite control center in the hypothalamus. In this study, the team of scientists gave Semaglutide to 28 people who had a body mass index (BMI) between 30-45 kg/m2.
The study participants were then divided into two groups, half of which got Semaglutide while the other half were given a placebo for 12 weeks. After 12 weeks, they were invited to a research center to attend lunch. The study participants were then asked to eat as much as they could until they were full, then a team of scientists recorded the food they ate.
After the results were analyzed, the team of scientists found that the average daily energy intake of study participants who got Semaglutide was 24% lower than the other group. Responding to the results of this study, a team of scientists stated that drugs that lower daily intake of food and also lower body fat will help people overcome obesity.
Dr. Julie Ingelfinger and Dr. Clifford Rosen of Tufts University, who was not involved in the study, called the study a “good start.” “The results were encouraging,” they wrote.
But they see great weakness. “First, the demographics in this trial do not reflect the U.S. population in general. Most of the participants were white, with only 6 percent Black or African American and 12 percent Latino, while nearly 40 percent of the U.S. population was non-White,” they wrote in a commentary in The New England Journal of Medicine.
It also doesn’t see long-term efficacy. “In short, we still have a long way to go to control the obesity epidemic,” they wrote.